Somewhat Favorable Press Coverage Somewhat Unlikely to Affect ResMed (RMD) Stock Price

News stories about ResMed (NYSE:RMD) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ResMed earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 45.9626476089518 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

RMD has been the topic of a number of recent research reports. J P Morgan Chase & Co lowered ResMed from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $72.00 to $71.00 in a research report on Thursday, April 20th. Bank of America Corporation lowered ResMed from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 2nd. Credit Suisse Group lowered ResMed from an “outperform” rating to a “neutral” rating in a research report on Tuesday, August 8th. BidaskClub lowered ResMed from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Finally, Zacks Investment Research downgraded ResMed from a “hold” rating to a “sell” rating in a research note on Wednesday, June 28th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $65.63.

ResMed (NYSE:RMD) traded up 0.36% on Wednesday, hitting $72.70. The stock had a trading volume of 467,971 shares. ResMed has a 1-year low of $56.59 and a 1-year high of $79.63. The firm has a market capitalization of $10.34 billion, a price-to-earnings ratio of 30.29 and a beta of 0.83. The company’s 50 day moving average is $76.11 and its 200-day moving average is $72.38.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.02. ResMed had a net margin of 16.56% and a return on equity of 21.99%. The company had revenue of $556.69 million for the quarter, compared to analysts’ expectations of $557.68 million. During the same quarter in the previous year, the firm posted $0.74 earnings per share. ResMed’s revenue for the quarter was up 7.3% on a year-over-year basis. On average, analysts forecast that ResMed will post $3.03 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 21st. Investors of record on Thursday, August 17th will be issued a $0.35 dividend. This is a positive change from ResMed’s previous quarterly dividend of $0.33. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $1.40 annualized dividend and a yield of 1.93%. ResMed’s payout ratio is presently 54.77%.

In related news, CFO Brett Sandercock sold 1,250 shares of the business’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $71.02, for a total value of $88,775.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Richard Sulpizio sold 65,887 shares of the business’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $77.82, for a total transaction of $5,127,326.34. Following the completion of the transaction, the director now owns 4,429 shares in the company, valued at approximately $344,664.78. The disclosure for this sale can be found here. In the last 90 days, insiders sold 204,650 shares of company stock worth $15,516,845. 1.97% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: This report was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://sportsperspectives.com/2017/08/16/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-resmed-rmd-stock-price.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply